This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 2
  • /
  • FDA approves Odactra to treat house dust mite (HDM...

FDA approves Odactra to treat house dust mite (HDM)-induced allergic rhinitis

Read time: 1 mins
Published:1st Feb 2023

ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts


ODACTRA is approved for use in persons 12 through 65 years of age.

Condition: Allergic Rhinitis/Dust Mite
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights